ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
mutation as a combination biomarker in predicting response to ICT in CheckMate275 and IMvigor210. Combination of the two biomarkers in baseline tumor tissues suggested improved OS compared to either single biomarker. Cumulatively, this study revealed that the combination of CXCL13 plus ARID1A may improve prediction capability for patients receiving ICT.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A retrospective analysis identified mutations in ARID1A in tumor tissues and expression of the chemokine CXCL13 as predictive biomarkers for ICT (170).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [170]
In the citing paper
“Importantly, the combination of ARID1A mutation plus CXCL13 showed improved predictive capacity compared with either of the single biomarkers alone (170).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [170]
In the citing paper
“Preclinical studies demonstrated association of ARID1A and CXCL13 with antitumor immunity in mice (170).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [170]
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21590 · Cited by 20,444
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400
Maftools: efficient and comprehensive analysis of somatic variants in cancer
Mayakonda, A., Lin, D.-C., Assenov, Y., Plass, C., & Koeffler, H. P. (2018) · Genome Research · doi:10.1101/gr.239244.118 · Cited by 4,935 · cited 1×
“The filtered mutation data were analyzed using the R package maftools (32).”
MethodIFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91190 · Cited by 3,788
Liu, J., Lichtenberg, T., Hoadley, K. A., Poisson, L. M., Lazar, A. J., Cherniack, A. D., Kovatich, A. J., Benz, C. C., Levine, D. A., Lee, A. V., et al. (2018) · Cell · doi:10.1016/j.cell.2018.02.052 · Cited by 3,725
Self-citationRosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669
Self-citationPembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613683 · Cited by 3,395
Comprehensive molecular characterization of urothelial bladder carcinoma
Weinstein, J. N., Akbani, R., Broom, B. M., Wang, W., Verhaak, R. G. W., Liu, W., Ju, Z., Motter, T., Peng, B., Ryan, M., et al. (2014) · Nature · doi:10.1038/nature12965 · Cited by 3,142
Self-citationComprehensive molecular characterization of urothelial bladder carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/za09-dk57 · Cited by 2,990
B cells and tertiary lymphoid structures promote immunotherapy response
Helmink, B. A., Reddy, S. M., Gao, J., Zhang, S., Basar, R., Thakur, R., Yizhak, K., Sade-Feldman, M., Blando, J., Han, G., et al. (2020) · Nature · doi:10.1038/s41586-019-1922-8 · Cited by 2,731
Self-citationComprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer
Robertson, A. G., Kim, J., Al-Ahmadie, H., Bellmunt, J., Guo, G., Cherniack, A. D., Hinoue, T., Laird, P. W., Hoadley, K. A., Akbani, R., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.007 · Cited by 2,443
Self-citationMPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Powles, T., Eder, J. P., Fine, G. D., Braiteh, F. S., Loriot, Y., Cruz, C., Bellmunt, J., Burris, H. A., Petrylak, D. P., Teng, S.-L., et al. (2014) · Nature · doi:10.1038/nature13904 · Cited by 2,381
Tertiary lymphoid structures improve immunotherapy and survival in melanoma
Cabrita, R., Lauss, M., Sanna, A., Donia, M., Skaarup Larsen, M., Mitra, S., Johansson, I., Phung, B., Harbst, K., Vallon-Christersson, J., et al. (2020) · Nature · doi:10.1038/s41586-019-1914-8 · Cited by 2,374
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
Cristescu, R., Mogg, R., Ayers, M., Albright, A., Murphy, E., Yearley, J., Sher, X., Liu, X. Q., Lu, H., Nebozhyn, M., et al. (2018) · Science · doi:10.1126/science.aar3593 · Cited by 2,301 · cited 2×
“A recent report showed that patients with high TMB plus high T cell GEP have better responses to ICT than TMB-high or GEP-high signature alone (27).”
BackgroundBalar, A. V., Galsky, M. D., Rosenberg, J. E., Powles, T., Petrylak, D. P., Bellmunt, J., Loriot, Y., Necchi, A., Hoffman-Censits, J., Perez-Gracia, J. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32455-2 · Cited by 2,199
Self-citationB cells are associated with survival and immunotherapy response in sarcoma
Petitprez, F., de Reyniès, A., Keung, E. Z., Chen, T. W.-W., Sun, C.-M., Calderaro, J., Jeng, Y.-M., Hsiao, L.-P., Lacroix, L., Bougoüin, A., et al. (2020) · Nature · doi:10.1038/s41586-019-1906-8 · Cited by 1,942
Tertiary lymphoid structures in the era of cancer immunotherapy
Sautès-Fridman, C., Petitprez, F., Calderaro, J., & Fridman, W. H. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0144-6 · Cited by 1,884 · cited 2×
“CXCL13 plays a critical role in lymphocyte infiltration as well as TLS formation (24).”
BackgroundSharma, P., Retz, M., Siefker-Radtke, A., Baron, A., Necchi, A., Bedke, J., Plimack, E. R., Vaena, D., Grimm, M.-O., Bracarda, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30065-7 · Cited by 1,736
Self-citationDavis, A. A., & Patel, V. G. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0768-9 · Cited by 960
Massard, C., Gordon, M. S., Sharma, S., Rafii, S., Wainberg, Z. A., Luke, J., Curiel, T. J., Colon-Otero, G., Hamid, O., Sanborn, R. E., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.9761 · Cited by 840
Stack, E. C., Wang, C., Roman, K. A., & Hoyt, C. C. (2014) · Methods · doi:10.1016/j.ymeth.2014.08.016 · Cited by 768
Sharma, P., Callahan, M. K., Bono, P., Kim, J., Spiliopoulou, P., Calvo, E., Pillai, R. N., Ott, P. A., de Braud, F., Morse, M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30496-x · Cited by 678
Self-citationPowles, T., Kockx, M., Rodriguez-Vida, A., Duran, I., Crabb, S. J., Van Der Heijden, M. S., Szabados, B., Pous, A. F., Gravis, G., Herranz, U. A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0628-7 · Cited by 591 · cited 1×
“Further, stromal cell–derived TGF signaling was associated with lack of response to ICT (16, 26), thereby highlighting the interaction of tumors and their immune ecosystem.”
BackgroundApolo, A. B., Infante, J. R., Balmanoukian, A., Patel, M. R., Wang, D., Kelly, K., Mega, A. E., Britten, C. D., Ravaud, A., Mita, A. C., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.6795 · Cited by 585
Shen, J., Ju, Z., Zhao, W., Wang, L., Peng, Y., Ge, Z., Nagel, Z. D., Zou, J., Wang, C., Kapoor, P., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0012-z · Cited by 562
Messina, J. L., Fenstermacher, D. A., Eschrich, S., Qu, X., Berglund, A. E., Lloyd, M. C., Schell, M. J., Sondak, V. K., Weber, J. S., & Mulé, J. J. (2012) · Scientific Reports · doi:10.1038/srep00765 · Cited by 426
CyTOF workflow: Differential discovery in high-throughput high-dimensional cytometry datasets
Nowicka, M., Krieg, C., Weber, L. M., Hartmann, F. J., Guglietta, S., Becher, B., Levesque, M. P., & Robinson, M. D. (2017) · F1000Research · doi:10.12688/f1000research.11622.1 · Cited by 403
CyTOF workflow: differential discovery in high-throughput high-dimensional cytometry datasets
Nowicka, M., Krieg, C., Crowell, H. L., Weber, L. M., Hartmann, F. J., Guglietta, S., Becher, B., Levesque, M. P., & Robinson, M. D. (2019) · F1000Research · doi:10.12688/f1000research.11622.3 · Cited by 399
EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer
Wang, L., Saci, A., Szabo, P. M., Chasalow, S. D., Castillo-Martin, M., Domingo-Domenech, J., Siefker-Radtke, A., Sharma, P., Sfakianos, J. P., Gong, Y., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05992-x · Cited by 313
Self-citationEpigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy
Li, J., Wang, W., Zhang, Y., Cieślik, M., Guo, J., Tan, M., Green, M. D., Wang, W., Lin, H., Li, W., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci134402 · Cited by 191 · cited 1×
“However, a recent preclinical study showed that aberrations in ARID1A can reduce sensitivity to ICT via an EZH2-mediated pathway (31).”
BackgroundBiomarkers for immunotherapy in bladder cancer: a moving target
Aggen, D. H., & Drake, C. G. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0299-1 · Cited by 187
ARID1A loss in cancer: Towards a mechanistic understanding
Mathur, R. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.05.001 · Cited by 159
Expression of p270 (ARID1A), a component of human SWI/SNF complexes, in human tumors
Wang, X., Nagl, N. G., Flowers, S., Zweitzig, D., Dallas, P. B., & Moran, E. (2004) · International Journal of Cancer · doi:10.1002/ijc.20450 · Cited by 93 · cited 1×
“ARID1A is a subunit of switch/sucrose nonfermentable (SWI/SNF) complex required for chromatin remodeling and known to interact with the transcription machinery (18).”
BackgroundImmune checkpoint inhibitors in urothelial cancer: recent updates and future outlook
Gopalakrishnan, D., Koshkin, V. S., Ornstein, M. C., Papatsoris, A., & Grivas, P. D. (2018) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s158753 · Cited by 66
Immune Checkpoint Therapy and the Search for Predictive Biomarkers
Sharma, P. (2016) · The Cancer Journal · doi:10.1097/ppo.0000000000000185 · Cited by 46 · cited 1×
“Notable efforts have been made for development of predictive biomarkers for patients with mUCC receiving ICT (12).”
BackgroundSelf-citationPredictive Biomarkers for Checkpoint Blockade in Urothelial Cancer: A Systematic Review
Lavoie, J., Black, P. C., & Eigl, B. J. (2019) · The Journal of Urology · doi:10.1097/ju.0000000000000136 · Cited by 30
Programmed Cell Death Ligand-1 Blockade in Urothelial Bladder Cancer: To Select or Not to Select
Drake, C. G., Bivalacqua, T. J., & Hahn, N. M. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.4696 · Cited by 24
Cited by
Immune checkpoint therapy—current perspectives and future directions
Sharma, P., Goswami, S., Raychaudhuri, D., Siddiqui, B. A., Singh, P., Nagarajan, A., Liu, J., Subudhi, S. K., Poon, C., Gant, K. L., et al. (2023) · Cell · doi:10.1016/j.cell.2023.03.006 · Cited by 1,206
Self-citationThe Next Decade of Immune Checkpoint Therapy
Sharma, P., Siddiqui, B. A., Anandhan, S., Yadav, S. S., Subudhi, S. K., Gao, J., Goswami, S., & Allison, J. P. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1680 · Cited by 750
Self-citationEnhancing anti-tumour efficacy with immunotherapy combinations
Meric-Bernstam, F., Larkin, J., Tabernero, J., & Bonini, C. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32598-8 · Cited by 409
Overcoming resistance to tumor-targeted and immune-targeted therapies
Aldea, M., Andre, F., Marabelle, A., Dogan, S., Barlesi, F., & Soria, J.-C. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1638 · Cited by 311
Targeting the DNA damage response in immuno-oncology: developments and opportunities
Chabanon, R. M., Rouanne, M., Lord, C. J., Soria, J.-C., Pasero, P., & Postel-Vinay, S. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00386-6 · Cited by 293
Metadata
- Authors
- Goswami, S., Chen, Y., Anandhan, S., Szabo, P. M., Basu, S., Blando, J. M., Liu, W., Zhang, J., Natarajan, S. M., Xiong, L., Guan, B., Yadav, S. S., Saci, A., Allison, J. P., Galsky, M. D., & Sharma, P.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Department of Translational Medicine, Bristol Myers Squibb, Princeton, NJ 08540, USA.
- Bristol-Myers Squibb (United States) (US)
- Tisch Cancer Institute (US)
- Corresponding author
- Sharma, Padmanee
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2020-06-17
- Volume
- 12
- Issue
- 548
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W3036281565
- Cited by
- 133
- References
- 36
- Citations by year
- 2026: 10 · 2025: 18 · 2024: 21 · 2023: 24 · 2022: 26 · 2021: 29 · 2020: 5
- FWCI
- 7.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Parker Institute for Cancer Immunotherapy
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- ARID1A mutation, immune checkpoint inhibitors, biomarkers, metastatic urothelial carcinoma, treatment response prediction, overall survival, IMvigor210
- MeSH terms
- Animals, Urinary Bladder Neoplasms, DNA-Binding Proteins, Humans, Mutation, Transcription Factors, Biomarkers, Tumor, Biomarkers, Mice, Chemokine CXCL13, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.